Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

110 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized phase III study evaluating dexamethasone-based mouthwash to prevent chemotherapy-induced stomatitis in patients with breast cancer.
Kuba S, Soutome S, Hagiwara Y, Kikawa Y, Iwamoto T, Sangai T, Harao M, Yamaguchi T, Taji T, Igarashi A, Kajimoto Y, Sakurai N, Yamanouchi K, Watanabe K, Maeda N, Suzuki M, Maeda S, Toh U, Ebata A, Iwakuma N, Matsunuma R, Yamaguchi M, Mukai H; CSPOR-BC. Kuba S, et al. Among authors: kikawa y. Jpn J Clin Oncol. 2024 Oct 1:hyae136. doi: 10.1093/jjco/hyae136. Online ahead of print. Jpn J Clin Oncol. 2024. PMID: 39354670
Oral Care Evaluation to Prevent Oral Mucositis in Estrogen Receptor-Positive Metastatic Breast Cancer Patients Treated with Everolimus (Oral Care-BC): A Randomized Controlled Phase III Trial.
Niikura N, Nakatukasa K, Amemiya T, Watanabe KI, Hata H, Kikawa Y, Taniike N, Yamanaka T, Mitsunaga S, Nakagami K, Adachi M, Kondo N, Shibuya Y, Hayashi N, Naito M, Kashiwabara K, Yamashita T, Umeda M, Mukai H, Ota Y. Niikura N, et al. Among authors: kikawa y. Oncologist. 2020 Feb;25(2):e223-e230. doi: 10.1634/theoncologist.2019-0382. Epub 2019 Oct 8. Oncologist. 2020. PMID: 32043762 Free PMC article. Clinical Trial.
The efficacy of sequential second-line endocrine therapies (ETs) in postmenopausal estrogen receptor-positive and HER2-negative metastatic breast cancer patients with lower sensitivity to initial ETs.
Iwamoto T, Fujisawa T, Shien T, Araki K, Sakamaki K, Sangai T, Kikawa Y, Takao S, Nishimura R, Takahashi M, Aihara T, Mukai H, Taira N. Iwamoto T, et al. Among authors: kikawa y. Breast Cancer. 2020 Sep;27(5):973-981. doi: 10.1007/s12282-020-01095-y. Epub 2020 May 11. Breast Cancer. 2020. PMID: 32394413 Free article.
Prospective Cohort Study of Combination Therapy With Abemaciclib and Hormonal Therapy for Chemotherapy-Treated Patients With Hormone Receptor-Positive Metastatic Breast Cancer.
Miyahara K, Narui K, Uemura Y, Yamada A, Araki K, Fujisawa F, Nakayama T, Ishikawa T, Taira N, Kikawa Y, Aihara T, Mukai H. Miyahara K, et al. Among authors: kikawa y. World J Oncol. 2022 Aug;13(4):216-221. doi: 10.14740/wjon1511. Epub 2022 Aug 23. World J Oncol. 2022. PMID: 36128594 Free PMC article.
Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2- metastatic breast cancer with low sensitivity to endocrine therapy.
Kikawa Y, Hagiwara Y, Fujisawa T, Araki K, Iwamoto T, Sangai T, Shien T, Takao S, Nishimura R, Takahashi M, Toyama T, Aihara T, Mukai H, Taira N. Kikawa Y, et al. PLoS One. 2022 Nov 29;17(11):e0278344. doi: 10.1371/journal.pone.0278344. eCollection 2022. PLoS One. 2022. PMID: 36445924 Free PMC article.
Hormonal Therapy Resistant Estrogen-receptor Positive Metastatic Breast Cancer Cohort (HORSE-BC) Study : Current Status of Treatment Selection in Japan.
Iwamoto T, Taira N, Fujisawa T, Araki K, Sakamaki K, Sangai T, Kikawa Y, Shien T, Takao S, Sato M, Goto Y, Yoshida T, Takahashi M, Aihara T, Mukai H. Iwamoto T, et al. Among authors: kikawa y. Acta Med Okayama. 2018 Aug;72(4):369-374. doi: 10.18926/AMO/56172. Acta Med Okayama. 2018. PMID: 30140084 Free article.
Oral care and oral assessment guide in breast cancer patients receiving everolimus and exemestane: subanalysis of a randomized controlled trial (Oral Care-BC).
Umeda M, Ota Y, Kashiwabara K, Hayashi N, Naito M, Yamashita T, Mukai H, Nakatsukasa K, Amemiya T, Watanabe KI, Hata H, Kikawa Y, Taniike N, Yamanaka T, Mitsunaga S, Nakagami K, Adachi M, Kondo N, Shibuya Y, Niikura N. Umeda M, et al. Among authors: kikawa y. Ann Transl Med. 2021 Apr;9(7):535. doi: 10.21037/atm-20-6488. Ann Transl Med. 2021. PMID: 33987233 Free PMC article.
Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial.
Saji S, Taira N, Kitada M, Takano T, Takada M, Ohtake T, Toyama T, Kikawa Y, Hasegawa Y, Fujisawa T, Kashiwaba M, Ishida T, Nakamura R, Yamamoto Y, Toh U, Iwata H, Masuda N, Morita S, Ohno S, Toi M. Saji S, et al. Among authors: kikawa y. Lancet Oncol. 2022 May;23(5):636-649. doi: 10.1016/S1470-2045(22)00196-6. Epub 2022 Apr 8. Lancet Oncol. 2022. PMID: 35405087 Clinical Trial.
Association of change in health-related quality of life and treatment discontinuation in metastatic breast cancer: a post hoc, exploratory analysis of two randomized clinical trials.
Kawahara T, Iwamoto T, Takashima I, Hanazawa R, Uemura K, Uemura Y, Mukai H, Kikawa Y, Taira N. Kawahara T, et al. Among authors: kikawa y. Support Care Cancer. 2022 Oct;30(10):8367-8375. doi: 10.1007/s00520-022-07283-0. Epub 2022 Jul 20. Support Care Cancer. 2022. PMID: 35857127 Free PMC article.
Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC.
Nakatsukasa K, Niikura N, Kashiwabara K, Amemiya T, Watanabe KI, Hata H, Kikawa Y, Taniike N, Yamanaka T, Mitsunaga S, Nakagami K, Adachi M, Kondo N, Shibuya Y, Hayashi N, Naito M, Yamashita T, Umeda M, Mukai H, Ota Y. Nakatsukasa K, et al. Among authors: kikawa y. BMC Cancer. 2021 Jan 7;21(1):34. doi: 10.1186/s12885-020-07746-9. BMC Cancer. 2021. PMID: 33413212 Free PMC article. Clinical Trial.
110 results